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fComparative Determinants of 4-Year Cardiovascular Event Rates in
Stable Outpatients at Risk of or With Atherothrombosis
Bhatt DL, Eagle KA, Ohman EM, and the REACH Registry Investigators.
JAMA 2010;304:1350-7.
Conclusion: Patients with vascular events are those at highest risk for
future cardiovascular death, myocardial infarction, and stroke.
Summary: Clinical trials of pharmacologic agents in patients with
atherosclerosis often report event rates in placebo groups lower than pro-
jected (Bhatt DL, N Engl J Med 2009;361:2330-41; Sacco RL, N Engl
J Med 2008;359:1238-51; and Topol EG, Lancet 2010;376:517-23). To
increase likelihood that a particular therapy might demonstrate benefit, it is
important to identify patients to participate in trials who are at high risk for
cardiovascular events. The REACH (Reduction of Atherothrombosis for
Continued Health) Registry consists of patients with various manifestations
of atherosclerosis varying from asymptomatic adults with risk factors to those
with stable atherosclerosis to those with prior ischemic events. In this study
the authors analyze the effects of prior ischemic events, polyvascular disease,
and diabetes mellitus with respect to future cardiovascular risk. Patients in
the REACH Registry were followed for up to 4 years. Patients were from
3647 centers in 29 countries enrolled between 2003 and 2004 and followed
up until 2008. The primary end point was a composite of cardiovascular
deaths, myocardial infarction, and stroke. Main outcome measures were
rates of cardiovascular death, myocardial infarction, and stroke.
There were 45,227 patients included in the 4-year analysis. During
follow-up, 5481 patients experienced at least one event; 2315 cardiovascular
deaths, 1228 myocardial infarctions, 1898 strokes, and 40 cases where
myocardial infarction and stroke occurred on the same day. Those with a
history of ischemic events at baseline (n  21,890) had the highest rate of
subsequent ischemic events (18.3%: 95% confidence interval [CI], 17.4%-
19.1%). Patients with stable coronary, cerebrovascular, or peripheral artery
disease (n  15,264) had a lower risk (12.2%; 95% CI, 11.4%-12.9%).
Patients with risk factors without established atherothrombosis (n  8073)
had the lowest risk (9.1%; 95%CI, 8.3%-9.9%; P .001 for all comparisons).
In multivariable modeling diabetes (hazard ratio [HR], 1.44; P .001), an
ischemic event in the previous year (HR 1.71; P  .01), and polyvascular
disease (HR, 1.99; P  .001) all were associated with increased risk of the
primary end point.
Comment: The data indicate polyvascular disease and a history of
ischemic events, particularly in the last year, are strongly associated with
cardiovascular death, myocardial infarction, and stroke. Many vascular sur-
gical patients would fall in to the high-risk groups. This perhaps explains, in
part, the high mortality rates of vascular surgical patients over time and
somewhat cynically may explain why vascular surgery patients tend to be
“repeat customers.” Once a patient with vascular disease has a cardiovascular
event they are much more likely to have additional events.
Standard Prophylactic Enoxaparin Dosing Leads to Inadequate
Anti-Xa Levels and Increased Deep Venous Thrombosis Rate in Criti-
cally Ill Trauma and Surgical Patients
Malinoski D, Jafari F, Ewing T. J Trauma 2010;68:874-80.
Conclusion: Standard prophylactic dosing of enoxaparin leads to low
anti-Xa levels in half of surgical intensive care unit patients with associated
increased risk of deep venous thrombosis (DVT).
Summary: DVT rates of those untreated intensive care unit (ICU)
patients range from 13% to 31% and up to 70% in severely injured patients.
Standard prophylaxis in higher-risk trauma or surgical patients includes
twice-daily dosing with enoxaparin (30 mg) but can still result in DVT rates
of 10% to 15%. Some patients experience altered pharmacokinetics and
pharmacodynamics of low-molecular-weight heparin (LMWH), reflected in
low trough anti-Xa levels with standard prophylactic dosing of LMWH. The
authors hypothesized that low anti-Xa levels would be found in critically ill,
trauma, and surgical patients treated with standard prophylactic doses of
LMWH and that such patients would have higher rates of DVT.
When there were no contraindications, surgical ICU patients were
treated with prophylactic enoxaparin and prospectively monitored. Anti-Xa
levels were drawn after the third dose. A trough level of0.01 IU/mL was
considered low. Screening venous duplex ultrasound exams were obtained at
48 hours of admission and then weekly. Excluded patients included those
who did not receive an ultrasound study, those who had a prior DVT, or if
anti-Xa trough levels were incorrectly obtained. Demographic data and
DVT rates were compared between patients with low and normal anti-Xa
levels. Fifty-four patients had a complete data set, of which 85% had an injury
severity score of 25  12. There were 74% men and 26% women, and 27
t
h
548atients (50%) had low anti-Xa levels. Those patients with low anti-Xa levels
ad more DVTs than those with normal levels (37% vs 11%, P  .026).
here were no differences between those with normal and low anti-Xa levels
ith respect to age, injury severity score, creatinine clearance, body mass
ndex, prevalence of high-risk injuries, and ICU/ventilator days.
Comment: The data provide at least a partial explanation for the
ontinued high rates of VTE complications in the injured patient despite
rotocols of chemical and mechanical VTE prophylaxis. It remains to be
een whether prophylactic dosing of LMWH stratified for anti-Xa levels
ould be both effective and cost effective in reducing VTE complications in
he injured patient or critically ill surgical patient.
andomized Clinical Trial of Mesh versus Sutured Wound Closure
fter Open Abdominal Aortic Aneurysm Surgery
evis PM, Windhaber RAJ, Lear PA, et al. Br J Surg 2010;97:1497-502.
Conclusion: Routine mesh placement reduces the rate of postopera-
ive incisional hernia after open abdominal aortic aneurysm (AAA) repair and
s not associated with increased complications.
Summary: There appears to be an increased risk of incisional hernia in
atients undergoing aortic surgery for an aneurysm compared with those
ndergoing aortic surgery for occlusive disease (Takagi H, Eur J Vasc
ndovasc Surg 2007;33:177-81). Rates of incisional hernia after AAA repair
ay be as high as 38% (Holland AJ, Eur J Vasc Endovasc Surg 1996;12:
96-200), and patients with AAA are postulated to have a connective tissue
isorder that increases susceptibility to incisional hernia (Adey B, Luna G,
m J Surg 1998;175:400-2). Prophylactic placement of prosthetic mesh in
he preperitoneal space during wound closure after open AAA repair may
esult in lower rates of incisional hernia (O’Hare JL, Eur J Vasc Endovasc
urg 2007;33;412-3).
The authors performed a randomized trial to see if mesh closure after
AA repair would result in fewer incisional hernias. Patients undergoing
pen AAA repair were randomized to routine abdominal mass closure or to
rophylactic placement of polypropylene mesh with abdominal wall closure.
he study included 85 patients (91% men) with a mean age of 73 years
range, 59-89 years). There were five perioperative deaths; none related to
esh. Hernia was determined by clinic examination or by ultrasound study.
uring follow-up, incisional hernia developed in 16 patients in the control
roup and in 5 in the mesh group (hazard ratio, 4.1; 95% confidence
nterval, 1.7.2-9.82; P .002). Hernia development occurred between 170
nd 585 days in the control group and between 336 and 1122 days in the
esh group. A minority of the hernias were repaired: four in the control
roup and one in the mesh group (P  .375). There were no mesh
nfections, but mesh was removed in one patient after seroma formation.
Comment: There are significant concerns regarding placement of
rophylactic polypropylene mesh. Certainly, mesh has been associated with
nfection and adhesion to underlying bowel. Although these complications
ere not noted in this series, the number of patients is small. The study does
onfirm a high rate of hernia formation in patients undergoing midline
ncisions for AAA repair and suggests hernia formation can be reduced by
rophylactic mesh replacement. The clinical significance of this is unclear
ecause the number of actual incisional hernia repairs was not statistically
ifferent in the patients undergoing routine mass closure vs those undergo-
ng prophylactic mass closure, implying many of the hernias perhaps were
mall or did not trouble the patient.
iabetes Mellitus, Fasting Blood Glucose Concentration, and Risk of
ascular Disease: A Collaborative Meta-Analysis of 102 Prospective
tudies
he Emerging Risk Factors Coalition. Lancet 2010;375:2215-22.
Conclusion: Diabetes confers a twofold excess risk for a wide range of
ascular diseases. This is independent from other conventional risk factors.
asting blood glucose concentration in people without diabetes is also
odestly, but not linearly, associated with risk of vascular disease.
Summary: The authors used data from 121 prospective studies of
ascular risk factors involving individual records of 1.27 million adults. All
tudies had accrued 1 year of follow-up. They used these data to produce
stimates of the association of diabetes and fasting blood glucose concen-
rations with fatal or first ever nonfatal incident vascular disease (and deaths
rom other vascular disorders) under a wide range of conditions.
Analyses included data for 698,782 people. There were 52,765 nonfa-
al or fatal vascular outcomes over 8.49million person-years at risk. Adjusted
azard ratios (HRs) for diabetes were 2.00 (95% confidence interval [CI],
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Volume 53, Number 2 Abstracts 5491.83-2.19) for coronary heart disease, 2.27 (95% CI, 1.95-2.65) for isch-
emic stroke, 1.56 (95% CI, 1.9-2.05) for hemorrhagic stroke, 1.84 (95% CI,
1.59-2.13) for unclassified stroke, and 1.73 (95% CI, 1.51-198) for aggre-
gate of other vascular deaths. Adjustments for lipid, inflammatory, or renal
markers did not appreciatively change the HRs. HRs for coronary heart
disease were higher in women than in men, at 40 to 59 years and at 70
years, and for fatal vs nonfatal disease. Assuming an adult population wide
prevalence of 10%, diabetes is estimated to account for 11% (95% CI,
10%-12%) of vascular deaths. There was no significant relationship to
vascular risk for blood glucose concentrations between 3.90 and 5.59
mmol/L. For patients with blood glucose concentrations 3.90 mmol/L,
HRs for coronary heart disease were 1.07 (95% CI, 0.97-1.18), for blood
glucose concentrations between 5.60 and 6.09 mmol/L the HR was 1.11
(95% CI 1.04-1.18), and for those with blood glucose concentrations
between 6.10 and 6.99 mmol/L, the HR was 1.17 (95% CI, 1.08-1.26).
Comment: There are a lot of numbers in this article. When one puts
the numbers in a public health perspective, the analysis is sobering. In
developed countries, 10% of vascular deaths result from diabetes. This
corresponds to an estimated 325,000 deaths per year. Results do not change
after adjustment for lipid, inflammatory, or renal markers. This means the
burden of vascular deaths will continue to increase as diabetes prevalence
continues to increase and this will happen even if cigarette smoking decreases
and there are further improvements in management of other vascular risk
factors. It is also important to note the increased burden of vascular disease
in patients with modestly elevated blood glucose concentrations that do not
meet the definition of diabetes mellitus. The ever-expanding obesity epi-
demic (no pun intended) will result in many hundreds of thousands of
diabetes related deaths over the next decade.
Effectiveness of Combination of Losartan Potassium and Doxycycline
versus Single-Drug Treatments in the Secondary Prevention of Tho-
racic Aortic Aneurysm in Marfan Syndrome
Yang HHC, Kim JM, Chung E. J Thorac Cardiovasc Surg 2010;140:
305-12.
Conclusion: The combination of losartan potassium and doxycycline
synergistically offers better aneurysm-suppressing effect in a mouse model of
Marfan syndrome than does either drug alone.
Summary: Marfan syndrome is autosomal dominant and results from
mutations in the gene encoding fibrillin-1. Abnormal aortic elastic fibers
result in altered load-bearing capacity of the aorta with degeneration,
fibrosis, and microdissection. Progression of thoracic aortic aneurysm in
Marfan syndrome is associated with upregulation of matrix metalloprotein-
ases (MMPs)-2 and MMP-9. Doxycycline inhibits MMP-2 and MMP-9
production and provides aneurysm suppressing effects in a mouse model of
Marfan syndrome (Chung AW, Circ Res 2006;99:140-8). Perturbations of
transforming growth factor (TGF)-may also contribute toMarfan syndrome.
TGF- can be antagonized with losartan potassium, an angiotensin-2 type-1
receptor antagonist. The authors hypothesize a combination of losartan potas-
sium and doxycycline would offer enhanced inhibition of aortic degeneration in
Marfan syndrome. A mouse model of Marfan syndrome (Fbn1C1039G//L)
was used in this study. Mice at 4 months of age, when aneurysm had been
established, were given doxycycline alone (0.24 g/L), losartan potassium alone
(0.6 g/L), or a combination of 0.12 g/L doxycycline and 0.3g/L losartan
potassium in drinking water. Littermate Fbn1/ mice served as controls.
Thoracic aortas were harvested and studied at 6 and 9 months.
Aortic diameter at 9 months increased in the untreated group by 40%
relative to controls. The aortic diameter was reduced by 10% in losartan
potassium-treated mice and by 16% in doxycycline-treated mice compared
with untreated aortas. Combination losartan potassium and doxycycline
completely prevented thoracic aortic aneurysm in the mouse model. There
was improvement in elastic fiber organization with downregulation of
MMP-2 and MMP-9, as well as downregulation of TGF-. Aortic contrac-
tile and relaxation functions also normalized compared with control values.
Comment: Combination drug treatment in a mouse model of Marfan
syndrome appears to offer potentially extraordinary secondary prevention
benefits. Although the mouse model may not be representative of all cases of
Marfan syndrome in humans, the mutation in the model is the most
common mutation in classic Marfan syndrome. Both drugs used for second-
ary prevention in this study are readily available, and it seems a human study
of combination therapy for prevention of aortic degeneration in patients
with Marfan syndrome should not be long off.
Venous and Cerebrospinal Fluid Flow in Multiple Sclerosis: A Case-
Control Study
Sundstrom P, Wahlin A, Ambarki K, et al. Ann Neurology 2010;68:255-9.
Conclusion: This study does not provide evidence confirming the
suggested vascular multiple sclerosis (MS) hypothesis.
Summary: The MS chronic cerebral spinal venous insufficiency hy-
pothesis suggests MS may develop secondary to impaired venous outflow
from the central nervous system (CNS). The implication is that stenosis of
8
1he veins draining the cerebral circulation may be potentially treated with
atheter-based techniques and lead to symptom improvement in patients
ith MS. Zamboni et al has reported stenoses of the veins draining the
erebral circulation are common in patients with MS and are basically never
een in those without MS (J Neurol Sci 2009;282:21-7). The hypothesis is
erebral venous insufficiency leads to accumulation of iron in the CNS and
riggers autoimmune events leading to MS. This possible link between MS
nd reported chronic cerebral spinal venous insufficiency is not generally
ccepted by MS neurologists at this time (Khan O, et al, Ann Neurol
010;67:286-90). In this current study, the authors used magnetic reso-
ance imaging (MRI) with phase contrast to evaluate flow direction of
ntercranial blood flow. Blood flow of the internal carotid arteries, the
ertebral arteries, and the internal jugular (IJ) veins as well as the anatomy of
he vessels was assessed in 21MS patients and 20 healthy controls usingMRI
hase-contrast imaging. Cases and control were matched for age (mean, 31
ears). There were 13 women and 8 men in theMS group and 8 women and
2 men in the control group. Patients with MS had a median duration of
isease of 5 years (range, 1-25 years).
The authors found no significant differences between controls and
atients with MS with respect to total IJ blood flow, the fraction of cerebral
lood flow returning through both IJ veins or either IJ vein, the prevalence
f IJ vein reflux, or any studied cerebrospinal fluid flow parameter. There
ere no significant differences between sexes for any parameter. Cases and
ontrols that had reflux both had markedly decreased IJ vein blood flow on
he effected side. A decreased blood flow fraction in one of the IJ veins was
enerally accompanied by compensatory increase of contralateral IJ vein
lood flow. In the 21 patients withMS, contrast-enhancedMR angiography
evealed no signs of venous stenosis in 18 patients and venous stenosis in 3.
ll stenosis were located in the middle portion of the IJ vein, and these
atients with stenosis had a corresponding decreased IJ vein flow as mea-
ured by phase-contrast MRI. The authors could find no typical pattern of
he IJ vein blood flow in the patients with MS.
Comment: The chronic cerebral spinal venous insufficiency hypothesis
s an etiology of MS has captured the attention of the medical community
nd, most especially, MS patients. This report is in sharp contrast with the
ndings of Zamboni et al (J Vasc Surg 2009;50:1348-53), in that the
uthors here are unable to demonstrate differences between cerebral spinal
enous drainage betweenMS cases and controls. The data here make it seem
ikely that any association between chronic cerebral spinal venous insuffi-
iency and MS will be weaker than previously reported. The study does not
rovide support for endovascular treatment of patients with MS. The MS
ommunity, neurologists, and all vascular interventionalists need to develop
rational and deliberate approach to assessment of this new hypothesis. At
his point it seems irresponsible, and perhaps unethical, for physicians to
ncourage expensive and, likely uncovered by insurance, endovascular treat-
ent of the highly vulnerable MS population.
ondaparinux for the Treatment of Superficial-Vein Thrombosis in the
egs
ecousus H, Prandoni P, Mismetti P, and the CALISTO Study Group. N
ngl J Med 2010;363:1222-32.
Conclusion: Fondaparinux is effective in the treatment of patients with
ymptomatic acute superficial venous thrombosis (SVT) of the legs.
Summary: Patients with isolated SVT may develop more serious
anifestations of venous thrombosis, with an 8.3% incidence of symptom-
tic venous thromboembolic (VTE) complications at 3 months and an
stimated 3% to 4% risk of deep venous thrombosis (DVT) or pulmonary
mbolism (PE; Decousus H, et al, Ann Intern Med 2010;152:218-24). To
elp clarify pharmacologic treatment of SVT, the authors conducted the
omparison of Arixtra and Lower Limb Superficial Vein Thrombosis With
lacebo (CALISTO) trial evaluating the efficacy of fondaparinux in reducing
ymptomatic VTE complications, or death, in patients with acute isolated
VT of the legs. There were 3002 patients with SVT 5 cm in length
ssigned to receive fondaparinux (2.5 mg subcutaneously, once daily) or
lacebo for 45 days. This was a randomized double-blind trial. Exclusion
riteria included concurrent DVT, known pulmonary embolism, SVT asso-
iated with sclerotherapy, SVT 3 cm of the saphenofemoral junction, a
revious SVT3months, or previous DVT or PE6months, patients with
condition predisposing to bleeding, or if they had major surgery within the
revious 3 months. Death from any cause, symptomatic PE, symptomatic
VT, symptomatic extension to the saphenofemoral junction, or symptom-
tic recurrence of SVT at day 47 all served as a composite primary end point.
he main safety outcome was major bleeding. Patients were monitored for
7 days.
Any component of the primary end point occurred in 13 of 1502
atients (0.9%) in the fondaparinux group and in 88 of 15,000 patients
5.9%) in the placebo group (relative risk reduction with fondaparinux, 85%;
5% confidence interval, 74%-92%; P  .001). All components of the
rimary efficacy end point were significantly reduced in the fondaparinux
roup with the exception of death (0.1% in both groups). PE or DVT was
5% lower in the fondaparinux group than in the placebo group (0.2% vs
.3%; 95% CI, 50-95%; P  .001). Based on relative risk reductions, 88
